Key Takeaway: REGENXBIO Inc. has scheduled a conference call for May 8, 2024, to discuss its financial results for the first quarter ending March 31, 2024, along with recent operational highlights. Listeners can register for the call via provided links, and a replay will be available shortly after the event. REGENXBIO, known for its advancements in gene therapy, is developing several innovative treatments for retinal and rare diseases. The company's AAV Therapeutics, including those developed in partnership with AbbVie, have the potential to significantly impact patient care.
Price reaction · baseline $15.35 (2024-04-30 close) · hit after-hours · clean, no other RGNX news in the window
day 0 close
+5.5%
day 1
+8.4%
day 3 · peak
+9.9%
Market Sentiment Analysis
POSITIVE FACTORS
REGENXBIO is hosting a conference call to discuss positive financial results.
The company is recognized as a leader in gene therapy.
REGENXBIO's AAV Therapeutics have shown promising potential for treating various diseases.
Recent collaborations with AbbVie and ongoing clinical advancements indicate strong operational progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+101%
120-day peak, hindsight
Typical move
8.4%
average across 5 past catalysts
Lead asset
RGX-202
Phase 2 · Duchenne Muscular Dystrophy
Full Press Release Details
ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
Corporate Communications
Chris Brinzey, ICR Westwicke
Frequently Asked Questions
When is REGENXBIO's Q1 2024 financial call scheduled?
The Q1 2024 financial call is on May 8, 2024, at 4:30 p.m. ET.
How can analysts join the Q&A session during the call?
Analysts can participate in the Q&A using the specified link provided in the announcement.
Where can I find the replay of the conference call?
The replay will be available on the company's investor website approximately two hours after the call.
What is REGENXBIO's focus as a biotechnology company?
REGENXBIO focuses on improving lives through the curative potential of gene therapy.
What is ABBV-RGX-314 used for?
ABBV-RGX-314 is designed to treat wet AMD and diabetic retinopathy.